These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6154898)

  • 21. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Strawitz JG; Weiss AJ; Yarbro JW
    Cancer Chemother Rep; 1974; 58(2):217-22. PubMed ID: 4133839
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
    Lomen PL; Baker LH; Neil GL; Samson MK
    Cancer Chemother Rep; 1975; 59(6):1123-6. PubMed ID: 56988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
    Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental therapy of sickle cell disease. Use of hydroxyurea.
    Charache S
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):62-6. PubMed ID: 7508689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-azacytidine in acute leukemia.
    Saiki JH; McCredie KB; Vietti TJ; Hewlett JS; Morrison FS; Costanzi JJ; Stuckey WJ; Whitecar J; Hoogstraten B
    Cancer; 1978 Nov; 42(5):2111-4. PubMed ID: 82472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea.
    Dover GJ; Charache S; Nora R; Boyer SH
    Ann N Y Acad Sci; 1985; 445():218-24. PubMed ID: 2409873
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of hydroxyurea treatment on free nucleotides in leukemic leukocytes].
    Maj S; Zdebska E
    Acta Haematol Pol; 1975; 6(3):211-6. PubMed ID: 1057841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-azacytidine in refractory acute leukemia.
    Case DC
    Oncology; 1982; 39(4):218-21. PubMed ID: 6178065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea treatment of myeloproliferative disorders. Macro-megaloblastic blood and bone marrow changes.
    Löfvenberg E; Nilsson T; Wahlin A; Jacobsson L
    Acta Med Scand; 1987; 222(2):169-74. PubMed ID: 3673669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.
    Schiffer CA; DeBellis R; Kasdorf H; Wiernik PH
    Cancer Treat Rep; 1982 Feb; 66(2):267-71. PubMed ID: 6173123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of variable doses of 5-azacytidine on fetal hemoglobin production in sickle cell anemia.
    Dover GJ; Charache SH
    Prog Clin Biol Res; 1984; 165():73-83. PubMed ID: 6209731
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine.
    Omura GA; Vogler WR; Bartolucci A; Neely CL; Silberman H
    Cancer Treat Rep; 1979 Feb; 63(2):209-10. PubMed ID: 87270
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea (NSC-32065) intermittent therapy in malignant diseases.
    Lerner HJ; Beckloff GL; Godwin MC
    Cancer Chemother Rep; 1969 Dec; 53(6):385-95. PubMed ID: 4915083
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I trial of cytarabine and hydroxyurea.
    Pfeifle CE; Howell SB
    Cancer Treat Rep; 1983 Dec; 67(12):1127-9. PubMed ID: 6652629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Oct; 56(5):649-52. PubMed ID: 4119908
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.